Key facts
- This page summarizes Richard W. Wagner's Form 4 filing for Eterna Therapeutics Inc. (ERNA).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 18 Jul 2023, 16:15.
Richard W. Wagner - 14 Jul 2023 Form 4 Insider Report for Eterna Therapeutics Inc. (ERNA)
- Reporting relationship
- Director
- Issuer ticker
- ERNA
- Reported as of
- 14 Jul 2023
- Net transaction value
- +$130,490
- SEC form
- 4
- Accepted by SEC
- 18 Jul 2023, 16:15:11 UTC
- Prior SEC filing
- 11 Jul 2023
- Next SEC filing
- 10 Aug 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Richard Wagner
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Richard W. Wagner filed Form 4 for Eterna Therapeutics Inc. (ERNA) on 18 Jul 2023.
Change
- Previous filing in this sequence was filed on 11 Jul 2023.
- Current net transaction value: +$130,490.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ERNA
transaction
Derivative
6.0% Senior Convertible Promissory Notes due 2028
Purchase
- Transaction value
- $120,000
- Shares
- Change %
- Price
- Shares after
- $120,000
- Date
- 13 Jul 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 41,958
- Exercise price
- $2.86
- Footnotes
- F1
ERNA
transaction
Derivative
Warrants (right to buy)
Purchase
- Transaction value
- $10,490
- Shares
- +83,916
- Change %
- Price
- $0.1250*
- Shares after
- 83,916
- Date
- 13 Jul 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 83,916
- Exercise price
- $2.61
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The reporting person entered into a Securities Purchase Agreement with the Issuer on July 13, 2023, pursuant to which, on July 14, 2023, the reporting person acquired $120,000 principal amount of the Issuer's 6.0% Senior Convertible Promissory Notes due July 2028 (the "Notes") and (ii) 83,916 warrants, each exercisable to purchase one share of the Company's common stock, par value $0.005 per share ("Common Stock"), at an exercise price of $2.61 per share (the "Warrants"), representing 200% of the number of shares of Common Stock issuable upon conversion of the Notes immediately after the issuance thereof. The conversion price for each Note included $0.25 ($0.125 for each Warrant share) in accordance with Nasdaq rules.